Table 3.
| Table 3A: Baseline Characteristics of HERS Subjects by β1AR49 and β1AR389 Genotype | ||||||||
|---|---|---|---|---|---|---|---|---|
|
β1AR49 Genotype (N=2172) |
β1AR389 Genotype (N=2139) |
|||||||
| Characteristic | Ser49/Ser49 (N=1641) |
Ser49/Gly49 (N= 477) |
Gly49/Gly49 (N= 54) |
p value | Arg389/Arg389 (N=1124) |
Arg389/Gly389 (N= 827) |
Gly389/Gly389 (N= 188) |
p value |
| Age (years) | 66.4 ± 6.6 | 66.5 ± 6.6 | 67.1 ± 6.2 | 0.73 | 66.6 ± 6.6 | 66.3 ± 6.6 | 66.1 ± 6.4 | 0.36 |
| Race | 0.63 | <.0001 | ||||||
| Caucasian | 1500 (91.4%) | 424 (88.9%) | 46 (85.2%) | 1049 (93.3%) | 732 (88.5%) | 157 (83.5%) | ||
| Afr-Am | 96 (5.9%) | 38 (8.0%) | 6 (11.1%) | 41 (3.7%) | 71 (8.6%) | 27 (14.4%) | ||
| Hispanic | 26 (1.6%) | 9 (1.9%) | 2 (3.7%) | 22 (2.0%) | 12 (1.5%) | 3 (1.6%) | ||
| Other | 19 (1.2%) | 6 (1.3%) | 0 | 12 (1.1%) | 12 (1.5%) | 1 ( 0.5%) | ||
| Diabetes | 357 (21.8%) | 99 (20.8%) | 9 (16.7%) | 0.61 | 237 (21.1%) | 180 (21.8%) | 46 (24.6%) | 0.55 |
| Prior MI | 843 (51.4%) | 234 (49.1%) | 27 (50.0%) | 0.67 | 581 (51.7%) | 422 (51.0%) | 87 (46.3%) | 0.39 |
| Current smoker | 190 (11.6%) | 61 (12.8%) | 8 (14.8%) | 0.62 | 124 (11.0%) | 107 (12.9%) | 23 (12.2%) | 0.43 |
| History of CHF | 191 (11.6%) | 54 (11.3%) | 3 (5.6%) | 0.38 | 121 (10.8%) | 103 (12.5%) | 24 (12.8%) | 0.45 |
| On β blocker at baseline | 538 (32.8%) | 159 (33.3%) | 20 (37.0%) | 0.80 | 382 (34.0%) | 265 (32.0%) | 58 (30.9%) | 0.54 |
| Hypertension | 563 (34.3%) | 160 (33.5%) | 18 (33.3%) | 0.95 | 394 (35.1%) | 284 (34.3%) | 50 (26.6%) | 0.075 |
| Table 3B: Baseline Characteristics of HERS Subjects by β2AR16 and β2AR27 Genotype | ||||||||
|---|---|---|---|---|---|---|---|---|
|
β2AR16 Genotype (N=2134) |
β2AR27 Genotype (N=2129) |
|||||||
| Characteristic | Gly16/Gly16 (N= 837) |
Gly16/Arg16 (N= 989) |
Arg16/Arg16 (N= 308) |
p value | Gln27/Gln27 (N= 742) |
Gln27/Glu27 (N=1010) |
Glu27/Glu27 (N= 377) |
p value |
| Age (years) | 66.5 ± 6.7 | 66.5 ± 6.5 | 66.4 ± 6.6 | 0.97 | 66.3 ± 6.6 | 66.4 ± 6.5 | 67.0 ± 6.6 | 0.28 |
| Race | <.0001 | <.0001 | ||||||
| Caucasian | 779 (93.1%) | 887 (89.7%) | 267 (86.7%) | 624 (84.1%) | 938 (92.9%) | 364 (96.6%) | ||
| Afr-Am | 41 (4.9%) | 74 (7.5%) | 24 (7.8%) | 74 (10.0%) | 58 (5.7%) | 9 (2.4%) | ||
| Hispanic | 12 (1.4%) | 21 (2.1%) | 4 (1.3%) | 23 (3.1%) | 12 (1.2%) | 2 (0.5%) | ||
| Other | 5 (0.6%) | 7 (0.7%) | 13 (4.2%) | 21 (2.8%) | 2 (0.2%) | 2 (0.5%) | ||
| Diabetes | 166 (19.9%) | 226 (22.9%) | 72 (23.5%) | 0.22 | 164 (22.1%) | 224 (22.2%) | 75 (20.0%) | 0.64 |
| Prior MI | 419 (50.1%) | 505 (51.1%) | 168 (54.6%) | 0.40 | 389 (52.4%) | 509 (50.4%) | 188 (49.9%) | 0.62 |
| Current smoker | 103 (12.3%) | 121 (12.2%) | 37 (12.0%) | 0.99 | 92 (12.4%) | 122 (12.1%) | 44 (11.7%) | 0.94 |
| History of CHF | 89 (10.6%) | 117 (11.8%) | 41 (13.3%) | 0.43 | 88 (11.9%) | 124 (12.3%) | 35 (9.3%) | 0.29 |
| On β blocker at baseline | 275 (32.9%) | 326 (33.0%) | 100 (32.5%) | 0.99 | 245 (33.0%) | 336 (33.3%) | 121 (32.1%) | 0.92 |
| Hypertension | 293 (35.0%) | 335 (33.9%) | 108 (35.1%) | 0.86 | 240 (32.4%) | 349 (34.5%) | 135 (35.8%) | 0.45 |